Leidos Secures Contract to Advance Health Research Initiatives for ARPA-H

RESTON, Va. - In a significant development for the health research sector, Leidos Holdings LDOS, a prominent Fortune 500® organization known for its innovation, has been granted a prime contract by the Advanced Research Projects Agency for Health (ARPA-H). The award is a testament to the company's expertise and trusted position in delivering scientific and technical services.

Contract Dynamics

The agreement between Leidos and ARPA-H is designed as a hybrid contract, incorporating both firm fixed price and time and materials elements. This structure underscores the flexibility and adaptability required in advanced health research projects, catering to the dynamic and evolving nature of the sector. Being a primary contract, Leidos is positioned at the forefront to catalyze transformative health advancements under the agency's directive.

Corporate Background

Leidos, operating under the ticker symbol LDOS, has a storied history, previously functioning as Science Applications International Corporation (SAIC). As a comprehensive conglomerate, Leidos has expanded its reach to include not just defense and aviation, but also cutting-edge sectors such as information technology reflecting its Lockheed Martin IS&GS origins, as well as biomedical research. Headquartered in Reston, Virginia, the company's service palette includes scientific studies, engineering skills, systems integration, and an array of technical services. By securing the ARPA-H contract, Leidos underscores its significant capabilities and dedication to fostering breakthroughs in health research.

Leidos, Contract, Health